To: rjk01 who wrote (5496 ) 5/25/2012 4:46:31 PM From: Gary Mohilner Read Replies (1) | Respond to of 5665 I never doubted they'd get the notice, but now they have 6 months, and if needed they can ask for 6 more, I'm hopeful that they won't need the extension. I actually did trade 100 shares of IMGN for nearly 3000 shares of AEZS this week. I still strongly believe IMGN could double by the end of next year, but if I'm right about AEZS in the same time it could be a ten banger or more. Frankly if the peek into the MM Trial for Perifosine results in continuing that trial, I think $1 to $2 could result from that alone, but before that happens at least the NDA for AEZS-130 should be filed, that ought to take the price above $1. The potentially biggest news for AEZS this year, IMHO, is if AEZS-130 works for Cancer Cachexia or not. If it does, what's currently thought of as a niche drug might truly reach blockbuster potential. I don't believe the company will partner the drug until they know. If Cachxia becomes part of the mix, I believe this is a potential partnership that's worth hundreds of millions up front if partnered worldwide to a single big Pharma partner. As for IMGN, I just read that Roche is being very public about its ASCO presentations, with an emphasis on T-DM1 which will be featured in a major oral presentation. I believe we could see highs not seen in over 10 years post ASCO. As we learn more about other drugs in the clinic, I believe awareness will grow of the breadth of IMGN's pipeline and with approval of T-DM1 and other drugs approaching or in Pivotal Trials, I believe new all time highs for IMGN quite possible. Not this year, but let's see where we are at ASCO 2013. Gary